» Articles » PMID: 22619646

Does Radiotherapy Have Curative Potential in Metastatic Patients? The Concept of Local Therapy in Oligometastatic Breast Cancer

Overview
Publisher Karger
Date 2012 May 24
PMID 22619646
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

In 1995, Hellmann and Weichselbaum defined for the first time the term oligometastases which is used to describe limited metastasis with a maximum of 3-4 clinically detectable metastases. It is assumed that these patients have a better prognosis and that local treatment of the metastases plays a significant part in the further development of the disease. Therefore, these patients could benefit from a curative local therapy of the manifested metastases. Local therapy measures include mainly radiotherapeutic methods alongside invasive ablative processes, such as surgical resection and radiofrequency ablation. Patients subjected to radiation therapy benefit especially from the usage of modern precision technology as it reduces the radiation exposure to the normal tissue, and because short radiation sessions with escalating doses are possible (e.g. radiation surgery, image-assisted radiation therapy, stereotactic radiation). Initial clinical studies show very good local tumor control rates which are on a par with resection and ablative methods, but with very few side effects and risks. This article summarizes the integration of the concept of oligometastases in the radiotherapy of limited metastatic breast cancer.

Citing Articles

The role of SBRT in oligometastatic patients with liver metastases from breast cancer.

Scorsetti M, Franceschini D, De Rose F, Comito T, Franzese C, Masci G Rep Pract Oncol Radiother. 2017; 22(2):163-169.

PMID: 28490988 PMC: 5411907. DOI: 10.1016/j.rpor.2016.07.008.


Assessment of Radiation Induced Therapeutic Effect and Cytotoxicity in Cancer Patients Based on Transcriptomic Profiling.

Karim S, Mirza Z, Chaudhary A, Abuzenadah A, Gari M, Al-Qahtani M Int J Mol Sci. 2016; 17(2):250.

PMID: 26907258 PMC: 4783980. DOI: 10.3390/ijms17020250.


Prognostic factors in breast cancer with extracranial oligometastases and the appropriate role of radiation therapy.

Yoo G, Yu J, Park W, Huh S, Choi D Radiat Oncol J. 2016; 33(4):301-9.

PMID: 26756030 PMC: 4707213. DOI: 10.3857/roj.2015.33.4.301.


Oligometastatic breast cancer: a shift from palliative to potentially curative treatment?.

Di Lascio S, Pagani O Breast Care (Basel). 2014; 9(1):7-14.

PMID: 24803881 PMC: 3995374. DOI: 10.1159/000358750.


The Challenge of Integrating Radiotherapy in the Multimodal Treatment of Breast Cancer.

Souchon R, Dunst J Breast Care (Basel). 2012; 6(5):345-346.

PMID: 22619642 PMC: 3357137. DOI: 10.1159/000334227.

References
1.
Cillo C, Dick J, Ling V, Hill R . Generation of drug-resistant variants in metastatic B16 mouse melanoma cell lines. Cancer Res. 1987; 47(10):2604-8. View

2.
Brito R, Valero V, Buzdar A, Booser D, Ames F, Strom E . Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol. 2001; 19(3):628-33. DOI: 10.1200/JCO.2001.19.3.628. View

3.
Tomlinson J, Jarnagin W, DeMatteo R, Fong Y, Kornprat P, Gonen M . Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007; 25(29):4575-80. DOI: 10.1200/JCO.2007.11.0833. View

4.
MacDermed D, Weichselbaum R, Salama J . A rationale for the targeted treatment of oligometastases with radiotherapy. J Surg Oncol. 2008; 98(3):202-6. DOI: 10.1002/jso.21102. View

5.
Bojko P, Welt A, Schleucher R, Borquez D, Scheulen M, Vanhoefer U . High-dose chemotherapy with autologous stem cell transplantation in patients with oligometastatic breast cancer. Bone Marrow Transplant. 2004; 34(7):637-43. DOI: 10.1038/sj.bmt.1704613. View